NTLA vs. OGN, ADMA, ALVO, RARE, VRNA, BHVN, CRNX, ACLX, APLS, and PTCT
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Organon & Co. (OGN), ADMA Biologics (ADMA), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), Verona Pharma (VRNA), Biohaven (BHVN), Crinetics Pharmaceuticals (CRNX), Arcellx (ACLX), Apellis Pharmaceuticals (APLS), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.
Intellia Therapeutics vs.
Intellia Therapeutics (NASDAQ:NTLA) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.
Intellia Therapeutics received 421 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 69.19% of users gave Intellia Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
In the previous week, Intellia Therapeutics had 3 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Intellia Therapeutics and 7 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.13 beat Intellia Therapeutics' score of -0.16 indicating that Organon & Co. is being referred to more favorably in the news media.
Intellia Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
Intellia Therapeutics presently has a consensus price target of $51.06, indicating a potential upside of 437.50%. Organon & Co. has a consensus price target of $21.33, indicating a potential upside of 35.32%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Intellia Therapeutics is more favorable than Organon & Co..
Organon & Co. has a net margin of 20.30% compared to Intellia Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 644.70% beat Intellia Therapeutics' return on equity.
Organon & Co. has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 3.2% of Intellia Therapeutics shares are owned by insiders. Comparatively, 1.4% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Intellia Therapeutics beats Organon & Co. on 10 of the 18 factors compared between the two stocks.
Get Intellia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NTLA) was last updated on 1/20/2025 by MarketBeat.com Staff
Free NTLA Stock Alerts